GlaxoSmithKline publishes detailed study results for malaria treatment
UK-based GlaxoSmithKline (LSE: GSK) and the Medicines for Malaria Venture (MMV) have published positive Phase III data from two studies of Krintafel (tafenoquine) for the radical cure of malaria.
The trials tested single-dose tafenoquine as a treatment for the Plasmodium vivax (P. vivax) strain of malaria. The results were published in The New England Journal of Medicine.
Based on the results from the studies, Krintafel was approved by the US Food and Drug Administration in July 2018, and subsequently in Australia, where it is marketed as Kozenis.
The disease is estimated to cause around 7.5 million clinical infections every year. The existing standard of care, primaquine, must be taken for 14 days, making compliance often low in endemic settings.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze